World Investment Advisors Raises Stock Holdings in United Therapeutics Corporation (NASDAQ:UTHR)

World Investment Advisors grew its position in United Therapeutics Corporation (NASDAQ:UTHR - Free Report) by 79.2% during the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 2,328 shares of the biotechnology company's stock after acquiring an additional 1,029 shares during the quarter. World Investment Advisors' holdings in United Therapeutics were worth $718,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other large investors have also added to or reduced their stakes in the company. Wealthfront Advisers LLC increased its position in shares of United Therapeutics by 2,090,573.5% during the 4th quarter. Wealthfront Advisers LLC now owns 18,314,300 shares of the biotechnology company's stock valued at $6,462,018,000 after purchasing an additional 18,313,424 shares during the last quarter. Vanguard Group Inc. increased its position in shares of United Therapeutics by 0.7% during the 4th quarter. Vanguard Group Inc. now owns 4,441,823 shares of the biotechnology company's stock valued at $1,567,253,000 after purchasing an additional 32,213 shares during the last quarter. FMR LLC increased its position in shares of United Therapeutics by 36.5% during the 4th quarter. FMR LLC now owns 1,471,405 shares of the biotechnology company's stock valued at $519,170,000 after purchasing an additional 393,777 shares during the last quarter. Geode Capital Management LLC increased its position in shares of United Therapeutics by 4.0% during the 4th quarter. Geode Capital Management LLC now owns 1,138,292 shares of the biotechnology company's stock valued at $401,184,000 after purchasing an additional 44,277 shares during the last quarter. Finally, AQR Capital Management LLC increased its position in shares of United Therapeutics by 0.8% during the 4th quarter. AQR Capital Management LLC now owns 975,444 shares of the biotechnology company's stock valued at $344,176,000 after purchasing an additional 7,710 shares during the last quarter. Institutional investors own 94.08% of the company's stock.

Insiders Place Their Bets

In other news, Director Raymond Dwek sold 3,000 shares of the stock in a transaction dated Monday, April 21st. The stock was sold at an average price of $285.57, for a total value of $856,710.00. Following the transaction, the director directly owned 1,750 shares of the company's stock, valued at approximately $499,747.50. This represents a 63.16% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Nilda Mesa sold 645 shares of the company's stock in a transaction dated Tuesday, June 24th. The stock was sold at an average price of $289.99, for a total value of $187,043.55. Following the completion of the sale, the director owned 4,883 shares in the company, valued at $1,416,021.17. The trade was a 11.67% decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders sold 76,681 shares of company stock valued at $22,813,739. Insiders own 10.30% of the company's stock.

United Therapeutics Stock Performance

NASDAQ:UTHR traded down $4.64 during mid-day trading on Friday, hitting $295.52. 296,534 shares of the company's stock traded hands, compared to its average volume of 501,765. The company has a fifty day moving average of $301.03 and a 200 day moving average of $320.77. United Therapeutics Corporation has a twelve month low of $266.98 and a twelve month high of $417.82. The company has a market capitalization of $13.33 billion, a P/E ratio of 11.79, a P/E/G ratio of 6.58 and a beta of 0.53.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last announced its earnings results on Wednesday, April 30th. The biotechnology company reported $6.63 earnings per share (EPS) for the quarter, beating the consensus estimate of $6.29 by $0.34. The company had revenue of $794.40 million for the quarter, compared to analyst estimates of $726.82 million. United Therapeutics had a return on equity of 19.33% and a net margin of 40.44%. The firm's quarterly revenue was up 17.2% compared to the same quarter last year. During the same period in the prior year, the company posted $6.17 EPS. On average, research analysts expect that United Therapeutics Corporation will post 24.48 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of equities analysts recently issued reports on the company. HC Wainwright restated a "buy" rating and set a $425.00 price objective on shares of United Therapeutics in a report on Monday, May 5th. Morgan Stanley dropped their price objective on United Therapeutics from $348.00 to $328.00 and set an "equal weight" rating for the company in a report on Thursday. Bank of America dropped their price objective on United Therapeutics from $321.00 to $315.00 and set a "neutral" rating for the company in a report on Wednesday, June 11th. JPMorgan Chase & Co. dropped their price objective on United Therapeutics from $350.00 to $330.00 and set an "overweight" rating for the company in a report on Tuesday. Finally, Wall Street Zen cut United Therapeutics from a "strong-buy" rating to a "buy" rating in a report on Friday, May 2nd. Four investment analysts have rated the stock with a hold rating and ten have issued a buy rating to the company's stock. According to data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $383.08.

United Therapeutics Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.